The Evolution of the Hemophilia Treatment Landscape

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, gives an overview of the different hemophilia therapies and recent improvements in the treatment landscape. 


So the treatment landscape up until recently hadn’t changed much. They started off in the 60s with cryoprecipitate and then they were able to do factor concentrates in the 70s and 80s. That was a huge improvement for patients; they could actually treat themselves at home and not have to come to the hospital. And then of course the 1980s came, HIV and hepatitis devastated the community. And then there was a push to develop recombinant products, so the ones that were not developed from human plasma.
So there’s been an evolution but there really hasn’t been any significant change up until recently. They’ve extended the half-life of the products so it lasts a little longer in the body. But all the therapies up until just recently have been through IV therapies. So that means you would have to start an IV with a butterfly needle to get the therapy in. And as anybody knows, young children don’t like needles, that hasn’t changed. And so the new therapies are a different route. Subcutaneous is obviously a preferred route for some of these new therapies. Emicizumab particularly is a subcutaneous drug so that’s really changed the landscape. It’s only for hemophilia A.

Most Popular

Related Articles

Turoctocog alfa pegol, also known as N8-GP (Esperoct, Novo Nordisk), is indicated for adults and children with hemophilia A.
A small mid-stage study demonstrated promising results for gene therapy candidate AMT-061 in patients with severe hemophilia B.
After discussing the impact hemophilia can have on one’s life, Doris V. Quon, MD, and patient Eric Mamos discuss potential ways to mitigate this impact and live a healthy life.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.